

Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)

**Date:** 06/09/2024

**Location:** Virtual

**Minutes:** Final

**Committee members present:**

Adam Firth	Chair	Present for notes 1 - 9
Ramsey Cutress	Topic Adviser	Present for notes 1 - 9
Mark Davies	Medical oncologist	Present for notes 1 – partway through 5, 6 - 9
Rachael Griffin	Lay member	Present for notes 1 - 9
Sadaf Haque	GP	Present for notes 1 - 9
Kwok Leung Cheung	Breast surgeon	Present for notes 1 - 9
Tim Robinson	Medical oncologist	Present for notes 1 - 6
David Talbot	Lay member	Present for notes 1 - 9
Katy Tan	Lay member	Present for notes 1 - partway through 5, 6 - 9
Ben Thwaites	Pharmacist	Present for notes 1 - 9

**In attendance:**

Victoria Carter	Implementation Support Manager	Present for notes 1 – partway through 6, 7 - 9
Lindsay Claxton	Health Economics Adviser	Present for notes 1 - 9
Rachel Gick	Technical Analyst (Observing)	Present for notes 1 - 9
Danielle Conroy	Project Manager	Present for notes 1 - 9
Charlotte Fairclough	Technical Analyst (Observing)	Present for notes 1 - 9
Gareth Haman	Senior Guidance Content Designer	Present for notes 1 - 9
Marie Harrisingh	Topic Lead	Present for notes 1 - 9
Yolanda Martinez	Technical Analyst	Present for notes 1 - 9
Adam Storrow	Business Analyst, Resource Impact Assessment	Present for notes 1 – partway through 8
Hannah Tebbs	Senior Health Economist	Present for notes 1 - 9

## Neoadjuvant chemotherapy & OFS update GC2 – minutes.

<b>Apologies:</b>	
Kay Davies-Crowley	Nurse specialist
Milly Finch	Pharmacist
Elinor Sawyer	Clinical oncologist
Sarah Boyce	Senior Technical Analyst
Andrea Heath	Senior Information Specialist, NICE
Adam O'Keefe	Project Manager, NICE
Katherine Saxby	Medicines Adviser, NICE

### 1. Welcome, introductions and apologies

The Chair welcomed the committee members and NICE attendees to the second committee meeting for the Neoadjuvant chemotherapy and ovarian function suppression update to the NICE Early and locally advanced breast cancer: diagnosis and management guideline.

The Chair informed the Committee that apologies had been received. These are noted above.

### 2. Declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Neoadjuvant chemotherapy and ovarian function suppression.

The Chair asked committee members to verbally declare any new interests, no new interests were declared.

### 3. Minutes of the last meeting

The Chair asked the group to ratify the minutes of the first meeting on 5<sup>th</sup> July which were circulated as part of the papers. All agreed that they were an accurate reflection of events.

### 4. TFS protocol queries and adverse events

The Chair introduced NICE Technical Adviser, Marie Harrisingh who presented several queries on the Testicular function suppression protocol for committee consideration. The committee discussed and provided input on relevant inclusions/exclusions, literature searches and adverse events.

### 5. Neoadjuvant chemotherapy for people with HER2 positive breast cancer

- Presentation of clinical evidence

The Chair introduced NICE Technical Analyst Yolanda Martinez who presented the clinical evidence identified for people with HER2 positive breast cancer. The committee

## Neoadjuvant chemotherapy & OFS update GC2 – minutes.

discussed the evidence presented and had the opportunity to ask any questions.
<b>6. Neoadjuvant chemotherapy for people with HER2 positive breast cancer</b> <ul style="list-style-type: none"><li>• Presentation of HE evidence</li><li>• Inequalities considerations</li><li>• Recommendation drafting</li></ul>
The Chair introduced NICE Health Economics Adviser Lindsay Claxton who presented the cost-effectiveness evidence identified for people with HER2 positive breast cancer. The committee discussed the evidence presented and any health inequalities considerations before drafting recommendations.
<b>7. Revisit TNBC and gBRCA recommendations &amp; discuss guideline restructuring</b>
NICE Technical Adviser Marie Harrisingh presented the recommendations and research recommendations for Triple negative breast cancer (Oestrogen or progesterone receptor negative and HER2 negative) and Germline BRCA mutation previously drafted and obtained committee input on possible amendments.  The Committee also discussed the current structure of the guideline and agreed to reorganise some sections to improve the flow of the guideline.
<b>8.</b> <ul style="list-style-type: none"><li>• <b>Looking at the new recommendations in situ in the systemic anticancer therapy section of the guideline</b></li><li>• <b>Looking at draft visual summaries for this section of the guideline.</b></li></ul>
NICE Technical Adviser Marie Harrisingh discussed the new recommendations in the context of the systemic anticancer therapy section of the guideline with the committee.  The committee were then presented with draft visual summaries produced in support of this guideline update. The committee discussed these, provided input and had the opportunity to ask any questions.
<b>9. AOB, Summary and next steps</b>
The Chair outlined next steps following the meeting, thanked the committee for their contributions, summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, the Chair brought the meeting to a close.

**Date of next meeting:** 27/09/2024

**Location of next meeting:** Virtual